RecruitingEarly Phase 1NCT07548697

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

Studying Dendritic cell sarcoma not otherwise specified

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Intervention: CT1182 injection(biological)
Enrollment: 24 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2026 – 2028

Study locations (1)

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Collaborators

CARsgen Life Sciences Co.,Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07548697 on ClinicalTrials.gov

← Back to all trials